Bio-Conscious Announces Breakthrough in Forecasting Nocturnal Hypoglycemia Events Using Machine Learning (ML) Techniques and CGM data.

VANCOUVER, BC / ACCESSWIRE / August 14, 2023 / Bio Conscious Technologies Inc. (“Bio Conscious Technologies” or the “Company”), a leading Artificial Intelligence (AI) innovator in healthcare/diabetes technology, has announced a breakthrough in forecasting high-risk diabetic events using CGM data and advanced Machine Learning (ML) techniques. The company’s latest achievement includes the publication of results for its nocturnal hypoglycemia detection model, showcasing its ability to detect these events up to 8 hours before they occur. Bio Conscious Technologies is excited to highlight its recent success in using the publicly available Ohio T1DM dataset, providing a benchmark for other companies to assess their capabilities.

This latest accomplishment builds upon Bio Conscious Technologies’ reputation for pioneering healthcare technology solutions. With its innovative use of machine learning algorithms, the company has proven its capacity to forecast high-risk medical events, including nocturnal hypoglycemia. By detecting these events well in advance, medical professionals, and patients can take proactive measures to prevent potentially life-threatening complications.

Amir Hayeri, CEO of Bio Conscious Technologies, shared his insights on this breakthrough: “We are pleased to announce the progress we’ve made in the field of healthcare technology. Our nocturnal hypoglycemia detection model sets a new standard, detecting events up to 8 hours before they occur. By releasing our results on the Ohio T1DM dataset, we’re inviting other companies to participate in this journey and aim for similar levels of accuracy and event horizon.”

The latest development is particularly promising for younger people with diabetes, who are susceptible to nocturnal hypoglycemia events. With Bio Conscious Technologies’ advanced preventive technology, patients and medical professionals alike can gain invaluable insights and tools to improve patient outcomes and reduce healthcare costs. The Company’s commitment to collaboration and innovation is further underscored by our decision to share their results openly. By publishing these breakthroughs and utilizing a standard dataset, Bio Conscious Technologies invites other companies to assess their internal testing and strive to match or exceed their event horizon and accuracy.

As Bio Conscious Technologies continues to push the boundaries of healthcare technology, our dedication to enhancing patient care remains at the forefront of our mission. This breakthrough has been achieved through Bio Conscious Technologies’ innovative use of ML algorithms, which anticipate high-risk diabetic events with higher accuracy based on CGM data. We believe this breakthrough represents a significant advancement in the field of Diabetes technology and has the potential to revolutionize the way medical professionals monitor and treat patients with Diabetes.

“This breakthrough is consistent with our vision to do more with CGM data. Specifically, we can use CGM data to forecast adverse glucose excursions with a much longer horizon (hours vs. minutes) and higher accuracy when compared to metabolic models that are currently available. This is just the beginning,” said Amir Hayeri, CEO of Bio Conscious Technologies. “Bio Conscious Technologies is proud to announce this groundbreaking achievement. Our AI breakthrough can potentially transform every aspect of the battle against diabetes through early detection and classification of Dysglycemia using CGMs.

Bio Conscious Technologies will publish more details about these models soon and welcomes hearing from parties interested in our technology. By making these models available on Amazon AWS, to third-party users, scientific organizations, and app developers, Bio Conscious is creating a new era of healthcare collaboration and innovation.

For more information on Bio Conscious Technologies and its breakthrough in healthcare technology, visit https://www.endobits.com/nocturnal-hypoglycemia.

About Bio Conscious Technologies

Bio Conscious Technologies is a leading innovator in healthcare technology and applied A.I., dedicated to developing innovative solutions to improve patient outcomes and reduce healthcare costs. With a focus on machine learning and artificial intelligence, Bio Conscious Technologies is at the forefront of the healthcare technology transformation.

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained in this press release, and other publicly available documents including the documents referenced herein, constitute forward-looking information or forward-looking statements (collectively, “forward-looking information)”. These statements relate to future events or future performance. The use of any of the words “anticipate”, “believe”, “could” “should”, “would”, “estimate”, “expect”, “forecast”, “indicate”, “intend”, “likely, “may”, “plan”, “potential”, “project”, “outlook”, “seek”, “target”, “trend” or “will” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the parties’ current belief or assumptions as to the outcome and timing of such future events. Examples of such forward-looking information include, without limitation, the new technology being able to anticipate medical events or prevent diabetes related complications; the accessibility of the models on Amazon AWS going forward; the ability of the new technology to improve patient outcomes or save lives; the ability of the new technology to revolutionize the way medical professionals monitor and treat patients; the ability of the Company to develop innovative solutions to improve patient outcomes and reduce healthcare costs; and the new technology being a breakthrough or a groundbreaking achievement in healthcare technology. Actual future results may differ materially. The forward-looking information contained in this release is made as of the date hereof and the parties are not obligated to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein. Many factors could cause actual results, level of activity, performance or achievements, or future events or developments to differ materially from those expressed or implied by the forward-looking information. All the forward-looking information made in this press release is qualified by these cautionary statements and other cautionary statements or factors in this press release. There can be no assurance that the actual results or developments will be realized or, even if substantially realized, will have the expected consequences to, or effects on, the Company. Unless required by applicable securities law, the Company does not intend and does not assume any obligation to update this forward-looking information.

For more information please contact:

Neil Clegg,
Neil@bioconscious.tech

SOURCE: Bio Conscious Technologies INC

View source version on accesswire.com:
https://www.accesswire.com/773903/Bio-Conscious-Announces-Breakthrough-in-Forecasting-Nocturnal-Hypoglycemia-Events-Using-Machine-Learning-ML-Techniques-and-CGM-data

Staff

Recent Posts

Daily Fit Notes Rolls Out Affordable Fitness Solutions for the Modern Lifestyle

Daily Fit Notes, founded by Justin Brey in New York, launches a text-based subscription fitness…

2 days ago

WillowWood Rebrand by DD.NYC Wins Gold Anthem Award for Product and Innovation in 2024 Rebrand

MT. STERLING, Ohio, Dec. 20, 2024 /PRNewswire/ -- WillowWood, a global leader in prosthetic solutions,…

2 days ago

Quantum Biopharma Announces Closing of Second Tranche

TORONTO, ON / ACCESSWIRE / December 20, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma"…

2 days ago

Glow Lifetech Announces Completion of Final Payment under Swiss Pharma Share Exchange Agreement and Debt Settlement

Toronto, Ontario--(Newsfile Corp. - December 20, 2024) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink:…

2 days ago